

Resource Summary Report

Generated by [SPARC SAWG](#) on Aug 15, 2026

pLentipuro3/TO/V5-GW/EGFP-Firefly Luciferase

RRID:Addgene_119816

Type: Plasmid

Proper Citation

RRID:Addgene_119816

Plasmid Information

URL: <http://www.addgene.org/119816>

Proper Citation: RRID:Addgene_119816

Insert Name: Luciferase

Organism: Photinus pyralis

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:30683938](#)

Vector Backbone Description: Backbone Size:8116; Vector Backbone:pLentipuro3/TO/V5-DEST; Vector Types:Mammalian Expression, Lentiviral, Luciferase; Bacterial Resistance:Ampicillin

Plasmid Name: pLentipuro3/TO/V5-GW/EGFP-Firefly Luciferase

Relevant Mutation: Stop codon removed in the frame of the V5 frame vector

Record Creation Time: 20220422T221626+0000

Record Last Update: 20260815T080316+0000

Ratings and Alerts

No rating or validation information has been found for pLentipuro3/TO/V5-GW/EGFP-Firefly Luciferase.

No alerts have been found for pLentipuro3/TO/V5-GW/EGFP-Firefly Luciferase.

Data and Source Information

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Monteagudo-García Ó, et al. (2026) ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation. *Cancer research*, 86(3), 622.

Chen W, et al. (2026) GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma. *International journal of molecular sciences*, 27(7).

Lam PY, et al. (2025) Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR. *Clinical and translational medicine*, 15(1), e70140.

Huang H, et al. (2025) Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance. *Nature communications*, 16(1), 4176.

Kumar A, et al. (2025) Resistance to radiation enhances metastasis by altering RNA metabolism. *Science advances*, 11(42), eadx3050.

Castiglione GM, et al. (2025) Running a genetic stop sign accelerates oxygen metabolism and energy production in horses. *Science (New York, N.Y.)*, 387(6741), eadr8589.

Jo H, et al. (2025) A fetal oncogene NUA2 is an emerging therapeutic target in glioblastoma. *EMBO molecular medicine*, 17(9), 2409.

Park C, et al. (2024) Murine alveolar macrophages rapidly accumulate intranasally administered SARS-CoV-2 Spike protein leading to neutrophil recruitment and damage. *eLife*, 12.

Pompili SVB, et al. (2024) In Vitro and In Vivo Studies of Melanoma Cell Migration by Antagonistic Mimetics of Adhesion Molecule L1CAM. *International journal of molecular sciences*, 25(9).

Chou CW, et al. (2023) Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination. *Nature communications*, 14(1), 6569.

Hung CN, et al. (2023) AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. *Cell reports*, 42(9), 113067.

Lamture G, et al. (2022) TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes. *Journal of immunotherapy (Hagerstown, Md. : 1997)*, 45(3), 139.

Pickering B, et al. (2022) Divergent SARS-CoV-2 variant emerges in white-tailed deer with deer-to-human transmission. *Nature microbiology*, 7(12), 2011.

Rossotti MA, et al. (2022) Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models. *Communications biology*, 5(1), 933.